The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can ...

Patients with glaucoma who are using prostaglandin F (FP) receptor agonists to control their disease may experience ...

A new study published in Biochemistry sheds light on how bacteria regulate their genes, challenging long-held assumptions about protein behavior. The research compares how two bacterial ...

A new study led by Dr. Rodrigo Maillard at Georgetown University, “Identifying Allosteric Hotspots in Mycobacterium tuberculosis cAMP Receptor Protein through Structural Homology,” published in ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...